GBG Forschungs GmbH (German Breast Group)

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024 (2024) Thill M, Janni W, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, et al. Journal article, Review article Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2024) Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C, Klare P, et al. Journal article Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference—a German expert perspective (2024) Krug D, Banys-Paluchowski M, Brucker SY, Denkert C, Ditsch N, Fasching P, Haidinger R, et al. Journal article, Review article Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy (2023) Huober J, van Mackelenbergh M, Schneeweiss A, Seither F, Blohmer JU, Denkert C, Tesch H, et al. Journal article RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial (2023) Link T, Blohmer JU, Schmitt WD, Kuhlmann JD, Just M, Untch M, Stoetzer OJ, et al. Journal article Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial (2023) Williams TM, Schneeweiss A, Jackisch C, Shen C, Weber KE, Fasching P, Denkert C, et al. Journal article Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023 (2023) Park-Simon TW, Müller V, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, et al. Journal article, Review article Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial (2023) Fasching P, Szeto C, Denkert C, Benz S, Weber K, Spilman P, Budczies J, et al. Journal article Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer (2023) Denkert C, Lambertini C, Fasching P, Pogue-Geile KL, Mano MS, Untch M, Wolmark N, et al. Journal article Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging (2023) Gonçalves JPL, Bollwein C, Noske A, Jacob A, Jank P, Loibl S, Nekljudova V, et al. Journal article